SPPS is often the method of choice for creating MAPs due to its efficiency and cost-effectiveness. The process involves the sequential addition of amino acids to a branched poly-lysine core, each branch potentially representing a different epitope. While this approach is less time-consuming and generally more cost-effective than conjugation methods, it is not without its challenges. The complexity of MAPs can lead to synthesis errors, resulting in microheterogeneity within the final product. Additionally, the solubility of peptide epitopes in MAP constructs can be unpredictable, particularly for longer sequences, which may affect the overall success of the synthesis.

The incorporation of an aminohexanoic acid (Ahx) linker into the lysine core of MAPs has been shown to improve yield, likely due to the increased solubility and reduced aggregation it offers during synthesis. These properties are essential for maintaining the solubility of growing peptide chains, thus enhancing the efficiency of MAP synthesis.

MAPs have broad applications in studying peptide-protein interactions, which are crucial for understanding cellular processes. Protein-peptide interactions, which constitute a significant portion of cellular interactions, can be explored using MAPs designed with various features to improve their interaction with target proteins. Strategies for enhancing the efficacy of MAPs include analyzing charged residues to improve solubility, using control peptides (such as scrambled sequences) for comparison, incorporating cell-penetrating peptides (CPPs) like the TAT sequence for enhanced cell entry, and adding spacers or linkers to increase molecular flexibility. Additionally, the use of D-amino acids can help avoid peptide degradation, and biotin conjugation allows for the facile pull-down of target proteins.

In summary, MAPs represent a powerful tool in the toolkit of molecular biologists and immunologists, facilitating detailed studies of immune responses and peptide-protein interactions. By leveraging MAPs’ unique advantages, including their ability to present multiple epitopes and enhance immunogenic responses, researchers can gain deeper insights into protein functions and interactions, vaccine development, and therapeutic peptide design. However, the successful application of MAPs requires careful consideration of their synthesis, solubility, and design to overcome potential limitations and achieve desired outcomes in scientific research.

However, DMSO’s application extends beyond cryopreservation, especially in dissolving hydrophobic peptides, which can be challenging to solubilize in aqueous solutions due to their inherent properties. The introduction of DMSO can enhance cell permeability, making it a valuable tool for delivering such peptides into cells. Yet, caution is necessary as DMSO concentrations exceeding 0.5% might induce cytotoxic effects, jeopardizing cell viability. While most cell lines can endure up to 0.5% DMSO with minimal cytotoxicity, primary cells often require even lower concentrations, not exceeding 0.1%, to avoid adverse effects​ (LifeTein)​.

To safely introduce peptides dissolved in DMSO into cell culture:

1. Dissolve peptides in a minimal volume of DMSO, aiming for a concentration that allows for further dilution in the cell culture medium.
2. Dilute the DMSO-peptide solution gradually in an aqueous buffer solution, such as PBS, to achieve the desired final peptide concentration in the cell culture. Vigilance is needed to prevent the solution from becoming turbid, indicating solubility limits have been reached. Sonication might aid in dissolving the peptides further​ (LifeTein)​.
3. Final concentration adjustment is crucial, ensuring that DMSO does not exceed safe levels for the cell type in culture. Keeping the final DMSO concentration around 0.1% is advisable to ensure compatibility with almost all cell lines. Up to 0.5% can be employed for applications necessitating higher DMSO concentrations, provided cell viability is not compromised​ (LifeTein)​.

By adhering to these guidelines, researchers can leverage DMSO’s solubilizing properties for hydrophobic peptides while minimizing potential cytotoxic effects on cell cultures. Including controls treated with DMSO alone in experiments is essential to discern any DMSO-related impacts from those of the peptide of interest. This balanced approach allows the exploration of peptide functions in cellular contexts without compromising cell health and experiment integrity.

Cell-penetrating peptides (CPPs) have emerged as revolutionary tools in biomedical research and therapy, particularly for their ability to facilitate the transport of cargo molecules across cell membranes. Their application spans drug delivery to vaccine development, providing a non-invasive and efficient method for transporting therapeutic molecules into cells.

CPPs, consisting of short sequences of amino acids, are known for their amphipathic and/or cationic nature, which enables them to interact with cellular membranes effectively. These peptides can transport a wide range of bioactive substances, including proteins, DNA, RNA, and nanoparticles, into cells, thus opening up new avenues for therapeutic interventions. The ability of CPPs to deliver cargo molecules into cells without disrupting the membrane integrity is a critical feature that distinguishes them from other delivery vectors.

In the realm of nanotherapeutics, CPPs have shown great potential in enhancing the delivery of therapeutic molecules into cells, thereby overcoming the challenges posed by the physicochemical properties of the delivery vehicles and the biological barriers. Their applications have been extensively explored in cancer therapy, where they improve the intracellular delivery of nanocarriers, facilitating tumor imaging and targeted drug delivery. Moreover, CPPs are being used to address other medical challenges, such as evaluating atherosclerotic plaques and HIV therapy, demonstrating their versatility in medical applications​.

CPPs also play a crucial role in vaccine development, where they are used to enhance the stability and delivery of antigens to immune cells. By fusing antigens with CPPs, researchers have been able to improve the presentation of antigens by antigen-presenting cells (APCs), leading to the induction of both humoral and cellular immunity. This strategy has been applied to the development of vaccines against various infectious diseases, showing promise in improving the effectiveness of vaccines​.

The therapeutic applications of CPPs extend beyond drug delivery and vaccine development. They have been explored in diagnosing and treating a range of human diseases, from cancer to infectious diseases, demonstrating their potential in clinical applications. The ability of CPPs to deliver mRNA and other genetic materials into cells has opened new possibilities for gene therapy and the development of mRNA vaccines​.

Despite the promising applications of CPPs, challenges remain in understanding their cellular entry and internalization mechanisms. This knowledge gap limits their more comprehensive clinical application. However, ongoing research continues to unravel the complexities of CPP-mediated delivery, with studies employing advanced techniques to quantify and understand the intracellular trafficking of CPPs and their cargo​.

In summary, CPPs represent a versatile and powerful tool in the advancement of therapeutic strategies, offering a non-invasive, efficient, and potentially transformative approach to drug delivery and vaccine development. Their ability to cross biological barriers and deliver a wide range of bioactive molecules into cells holds significant promise for the future of medicine.

1. Peptide Stability: Peptide stability can vary widely. Some peptides are more stable than others. Factors like amino acid composition, sequence, and post-translational modifications can influence stability.

2. Preservatives: Some peptides are more stable when reconstituted in a buffer containing preservatives, such as sodium azide or phenol red. These additives can help inhibit bacterial growth and extend the shelf life of the peptide solution.

3. Storage Temperature: Refrigeration at 2-8°C is the standard storage temperature for reconstituted peptides. Storing at lower temperatures, such as -20°C or -80°C, can extend the shelf life significantly.

4. Container Type: Using airtight and sterile containers can help prevent contamination and improve stability.

5. Handling: Avoid frequent freeze-thaw cycles, as they can degrade peptides. If you need to use the peptide multiple times, aliquot it into smaller portions to minimize freeze-thaw cycles.

6. pH: The pH of the peptide solution can also affect stability. Ensure that the pH is within the recommended range for the specific peptide.

7. Manufacturer’s Recommendations: Check the manufacturer’s guidelines for the recommended storage conditions and shelf life of the specific peptide you are using.

In general, reconstituted peptides stored in the refrigerator (2-8°C) can remain stable for several days to a few weeks. However, for longer-term storage, especially if you want to extend the shelf life, it’s advisable to aliquot the peptide into small portions and store them at lower temperatures, such as -20°C or -80°C. This can extend the shelf life for several months to a year or more, depending on the peptide’s stability.

Always follow the manufacturer’s instructions and recommendations for the specific peptide you are working with, as they may provide more accurate information on storage and stability. Additionally, keep detailed records of the date of reconstitution and storage conditions to help you track the shelf life and ensure the quality of your peptide solutions.

Materials and Reagents:

1. Peptide of interest
2. Dimethyl sulfoxide (DMSO)
3. Sterile, nuclease-free, and pyrogen-free microcentrifuge tubes
4. Sterile, nuclease-free, and pyrogen-free pipette tips
5. Sterile phosphate-buffered saline (PBS) or cell culture medium
6. Sterile cell culture plates or dishes
7. Cells for culture
8. Appropriate culture medium

Procedure:

1. Prepare a Clean Workspace:

   • Ensure that your work area is clean and sterile. Use a laminar flow hood or biosafety cabinet if available.

2. Peptide Weighing:

   • Weigh the appropriate amount of LifeTein peptide according to your experimental needs using a calibrated analytical balance. Use a clean spatula or microspatula for handling.

3. Prepare DMSO Stock Solution:

   • Use a sterile and dry microcentrifuge tube to prepare a stock solution of DMSO. Make sure the tube is pyrogen-free and nuclease-free.
   • Add the required volume of DMSO to the tube. DMSO is a common solvent for peptides, and the amount will depend on the peptide’s solubility and your desired concentration.
   • Be cautious when using DMSO; it can readily permeate the skin, so wear appropriate personal protective equipment (PPE), such as gloves and lab coat.

4. Peptide Dissolution:

   • Slowly add the weighed peptide to the DMSO in the tube while gently vortexing or pipetting. It may take some time for the peptide to dissolve completely.
   • Avoid vigorous mixing to minimize the introduction of air bubbles.

5. Dilution for Cell Culture:

   • Once the peptide is fully dissolved in DMSO, you will need to dilute it further for cell culture to reach the desired working concentration.
   • To do this, add the DMSO-peptide solution dropwise to sterile PBS or cell culture medium while gently mixing. Continue mixing until the DMSO-peptide solution is well-diluted and homogenous.

6. Final Concentration:

   • Calculate the final concentration of DMSO in the cell culture medium. Ensure it is within a range that is not toxic to your cells. DMSO concentrations of 0.1% or lower are generally considered safe for most cell lines, but you should verify this for your specific cell type.

7. Cell Culture:

   • Aspirate the old cell culture medium from your cells.
   • Add the diluted DMSO-peptide solution to the cells, replacing the old medium. The final peptide concentration should be appropriate for your experiment.
   • Incubate your cells under normal culture conditions.

8. Controls and Optimization:

   • Include appropriate controls in your experiments, such as cells treated with DMSO alone, to assess potential DMSO-related effects.

9. Monitoring and Assaying:

   • Monitor your cells during the course of your experiment to assess their viability and functionality.

Remember that the solubility of peptides can vary, so you may need to adjust the DMSO concentration or consider alternative solvents if you encounter difficulties. Always work with sterile materials, follow appropriate safety precautions, and ensure that the DMSO concentration remains within a range that is safe for your specific cell type.

1. Specificity: Peptide design determines the specificity of the antibodies produced. Antibodies are highly specific, binding to particular epitopes (specific regions) on antigens. If the designed peptide does not accurately mimic the target epitope, the antibodies generated may not recognize the intended target, leading to false results or a lack of efficacy.

2. Antigenicity: The chosen peptide should be antigenic, meaning it should elicit an immune response when used to immunize animals. A poorly designed peptide may not induce a strong immune response, resulting in low antibody titers or non-functional antibodies.

3. Cross-reactivity: In some cases, a peptide may share similarities with other proteins or antigens. Poor peptide design can lead to cross-reactivity, where antibodies generated against the target peptide also bind to unrelated molecules. This can result in non-specific binding and potentially inaccurate experimental results. LifeTein designs your peptides for free. 

4. Structural Considerations: If the target antigen has a specific 3D structure or conformational epitopes, the peptide design must take this into account. Linear peptides may not accurately represent these epitopes, necessitating the use of alternative strategies, such as using peptide libraries or designing cyclic peptides.

5. Adequate Length: Peptide length is critical. Peptides that are too short may lack the necessary information for proper antibody binding, while excessively long peptides can be challenging to synthesize and may not be as immunogenic.

6. Amino Acid Composition: The choice of amino acids in the peptide sequence is crucial. Natural amino acids, especially those found in the target antigen, are typically used. Proper selection ensures that the peptide closely mimics the target and increases the likelihood of generating functional antibodies.

7. Conjugation: In some cases, the peptide needs to be conjugated to carrier proteins to enhance its immunogenicity. The design of the conjugation strategy, including the linker used and the orientation of the peptide on the carrier, can impact the immune response and antibody production.

8. Experimental Efficiency: Proper peptide design can save time and resources. Using a well-designed peptide reduces the likelihood of failed experiments and minimizes the need for additional optimization steps.

9. Ethical Considerations: In animal immunization studies, using a well-designed peptide minimizes the number of animals needed for antibody production, which is important from an ethical standpoint.

Correct peptide design is essential for generating functional antibodies with high specificity and affinity for their target antigens. It ensures that the antibodies generated through immunization accurately recognize the desired epitopes, leading to reliable experimental results and successful applications in research, diagnostics, and therapeutics. Careful consideration of peptide properties and characteristics is fundamental to the success of antibody generation projects.

RGD products: 

• biotin-Ahx-PPPPRGDRGDRGD-NH2
• Cyclo RGD peptide, CRGDKGPDC-NH2

More information about the RGD peptides. 

Usage Instructions:

Note: These recommendations should be used as guidelines to determine the optimal coating conditions for your culture system. All operations should be performed in a laminar flow hood to maintain sterility. Two procedures are provided: Procedure A and Procedure B.

Procedure A:

1. Remove the cap and add 5 ml of serum-free medium or PBS to the bottle.

2. Replace the cap and vigorously vortex the contents. Make sure that the RGD peptide is completely dissolved. The solution will remain slightly cloudy.

3. Transfer the desired volume of the solution from the bottle to a dilution vessel. Dilute it to the desired concentration using a serum-free medium or PBS. A typical working concentration may range from 0.1 to 10 μg/ml.

4. Add the appropriate amount of diluted material to the culture surface.

5. Incubate at room temperature or 37°C, covered, for 1-2 hours.

6. After incubation, remove any remaining material.

7. Carefully rinse the plates with dH2O, avoiding scratching the bottom surface of the plates.

8. The plates are now ready for use. They may be stored at 2-10°C, air-dried, as long as sterility is maintained.

9. Store any remaining solubilized RGD peptide at 2-10°C.

Note: To achieve optimal cell binding, the cell attachment solution should include divalent cations (Calcium, Magnesium, or Manganese).

Procedure B:

1. Remove the cap and add 5 ml of sterile 70% ethanol.

2. Replace the cap and vortex the contents. Make sure that the RGD peptide is completely dissolved.

3. Transfer the desired volume of the solution from the bottle to a dilution vessel. Dilute it to the desired concentration using 70% ethanol. Concentrations from 0.1 to 10 μg/ml should be tested.

4. Add the appropriate amount of diluted material to the culture surface.

5. Leave the coated container uncovered in a laminar flow hood until the wells are dry.

6. Carefully rinse the plates with dH2O, avoiding scratching the bottom surface of the plates.

7. The plates are now ready for use.

8. Store any remaining solubilized RGD peptide at 2-10°C.

Labeled peptides are frequently used by researchers for binding studies, to determine substrate specificity, and for receptor cross-linking studies. Many researchers would like to synthesize biotin, FITC, nanoparticle, or drug-labeled peptides. It is suggested that a new strategy, using Rink amide 4-methylbenzhydrylamine resin coupled with Fmoc-Lys(Dde)-OH, be used. The major advantage of this approach is that other labels such as FITC, dansyl groups, methyl coumarin, and potentially fluorophores and quenchers used for fluorescence resonance energy transfer (FRET) can be directly incorporated into peptides.

How much protein antigen do I need to send?

We recommend sending 4-6 mg and 90% purity of the antigen for a rabbit project. We recommend 0.5 mg/ml as a minimum protein concentration and welcome higher concentrations.

Does LifeTein guarantee antibody titer?

LifeTein guarantees at least a 1:32,000 antibody titer against peptide sequences that we synthesize/conjugate. Titers are confirmed via ELISA tests.

Peptide synthesis protocol

Take peptide Biotin-Ahx-LPETGS-NH2 for example.

The Fmoc solid phase synthesis method was used for peptide production. Peptides were synthesized from the C-terminus to the N-terminus in this method. In peptide synthesis, an amino-protected amino acid Fmoc-Ser-OH was bound to a solid phase material (wang resin), forming a covalent bond between the carbonyl group and the resin (Fmoc-Ser-Wang resin). It was swollen by DCM, then the amino group fmoc was deprotected by piperidine, washed by DMF, and reacted with the carbonyl group of the next amino acid Fmoc-Gly-OH, with the help of HBTU in half an hour. The Kaiser test was taken to detect free ammonia. This cycle was repeated to form the desired peptide chain. For the last step of Biotin conjugation, the fmoc group of the N terminus leu was deprotected and reacted with Biotin.

After all reactions were completed, the synthesized peptide was cleaved from the resin. The reagent K was TFA/TIS/water (95%/2.5%/2.5%). MS was performed to detect the M.W. The purification was under reverse-HPLC, C18 column, and 220nm wavelength preparation conditions.

Do I retain rights to the antibody and peptides produced by LifeTein?

You will receive all peptides and antibodies and retain rights to these materials. Your peptide sequence and protein information remain confidential and we will never release details of any potential, current, or past projects to any outside parties.

How to solubilize my synthetic peptides?

Please refer to this FAQ for details: Handling and Storage of Synthetic Peptides.
If the peptides are still cloudy, or turbid, you may have reached the limit of solubility. When the peptides are insoluble in the buffer, please try to sonicate, centrifuge, and lyophilize the peptide. Make sure to break the lyophilized lumps into a fine powder. Then try a small volume of a good agent 8M Urea, NMP, DMF, or DMSO to dissolve the peptide. Then dilute with water or your desired buffer. For peptides with Arg or LYs, you should try to lower the pH to 6 because the protonated amino acids will help solubility.

Sonication and the following solvents may help with difficult peptides:
1) Begin with 100 % acetonitrile then dilute with water until 50%
2) Begin with 100% DMSO then dilute with water until 30 %
3) Dissolve it with 8M Urea
4) Dissolve it with 6 or 8 M Guanidine hydrochloride
5) 6M GuHCL, 0.05% TFA, pH2,
6) 100% TFA
7) 40% AcOH, 30%ACN, 30% water

CPPs such as the HIV Tat sequence and poly-arginine (R8 or R9) have been extensively studied for their potential in gene delivery systems. The basic amino acids within these peptides interact with the negatively charged phosphate groups of nucleic acids, facilitating the formation of complexes that can efficiently penetrate cell membranes (MDPI). This interaction is primarily driven by electrostatic attraction, leading to DNA condensation and enhancing cell uptake (PLOS).

In practical applications, CPPs have shown promise for the development of transgenic plants, where traditional methods such as Agrobacterium-mediated transformation or virus-based vectors face limitations in host specificity, safety concerns, and efficiency. The use of CPPs in non-viral, peptide-based gene delivery systems has gained popularity due to their ability to deliver nucleic acids across the natural barrier of the cell membrane without the need for specific receptors or channels (MDPI). This approach has the advantage of being applicable to a wide range of cell types, including difficult-to-transform species, thereby broadening the scope of genetic engineering and molecular studies.

For the preparation of peptide-DNA complexes, a protocol involving dissolving peptides and DNA in Hepes buffer, followed by mixing the peptide solutions with DNA to form complexes of varying compositions, has been suggested. Adjusting the final DNA concentration and storing complex solutions before use are critical steps. Moreover, the N/P ratio, which represents the ratio of amino and guanidino groups in peptides to phosphate groups in DNA, is essential for optimizing transfection efficiency. The fluorescence intensities of these complexes can then be measured to evaluate their stability and potential for gene delivery (PLOS).

Advances in CPP technology and exploration of various chemical modifications have significantly improved cellular uptake and delivery efficiency. Modifications such as peptide cyclization and the incorporation of D-amino acids have been explored to enhance the stability and internalization efficiency of CPPs, thereby making them more effective for delivering therapeutic agents, including anti-cancer drugs and genetic material, into target cells (MDPI).

Overall, the use of cell-penetrating peptides in DNA and plasmid studies offers a promising avenue to enhance gene delivery efficiency in both research and therapeutic contexts. As this field continues to evolve, further optimizations in CPP design and delivery mechanisms are expected to improve the specificity and efficacy of gene transfection techniques, opening new pathways for the development of novel therapeutic strategies and the study of gene function.

Sample Protocol

1. The peptide and DNA were dissolved separately in 10 mM Hepes buffer (pH 7.3).
2. A two-fold excess volume of peptide solutions of various concentrations was added to the DNA solution to form peptide/pDNA complexes with different compositions.
3. The final DNA concentration was adjusted to 30 μg/mL, and complex solutions were stored at room temperature for 15 min before use.
4. The N/P ratio (2, 4, or 8) was defined as the residual molar ratio of the amino and guanidino groups of amino acids in the peptides to the phosphate groups of DNA.
5. The fluorescence intensities of peptide/pDNA solutions prepared at various N/P ratios were measured using a spectrofluorometer (ND-3300).

Dimethyl sulfoxide (DMSO) is an organic compound with the formula of (CH3)2SO. DMSO is frequently used in cell banking applications as a cryoprotectant. DMSO prevents intracellular and extracellular crystals from forming in cells during the freezing process. For most cryopreservation applications, DMSO is used at 10% concentration and is usually combined with saline or serum albumin.

Hydrophobic peptides can be easily dissolved in DMSO. However, peptides in DMSO could be cytotoxic to the cells although DMSO increases cell permeability. A high concentration of DMSO should never be used for cell culture. 5% is very high and will be dissolving the cell membranes. Most cell lines can tolerate 0.5% DMSO and some cells can tolerate up to 1% without severe cytotoxicity. However, primary cell cultures are far more sensitive. So if it is the primary cell you are using then do a further dose/response curve (viability) at concentrations below 0.1%.

So for very hydrophobic peptides, try to dissolve the peptide in a small amount of DMSO (30-50ul, 100%), and then slowly drop the solution to a stirred aqueous buffer solution like PBS or your desired buffer to the desired concentration. If the resulting peptide solution begins to show turbidity, you have reached the limit of solubility. Sonication will help to dissolve the peptides.

Rule of thumb:

• 0.1% DMSO is considered to be safe for almost all cells.
• 0.5% DMSO as the final concentration has been used widely for cell culture without cytotoxicity.
• 1% DMSO doesn’t cause any toxicity to some cells but 0.5% DMSO is recommended.
• 5% DMSO was used successfully for some cells.

To keep the final concentration to 0.5%, you can make 200x stock in 100% DMSO.